<DOC>
	<DOCNO>NCT00151125</DOCNO>
	<brief_summary>This study test use rhIL-11 ( recombinant interleukin 11 , Neumega ) individual Von Willebrand disease . The purpose evaluate : 1. rhIL-11 corrects VWF ( Von Willebrand Factor ) level normal 2. rhIL-11 DDAVP together boost VWF level even high 3. onset , peak , duration rhIL-11 effect 4. rhIL-11 safe individual Von Willebrand Disease</brief_summary>
	<brief_title>Phase II Study IL-11 ( Neumega ) Von Willebrand Disease</brief_title>
	<detailed_description>This prospective , single center , open-label , escalate dose Phase II comparison study interleukin-11 ( rhIL-11 , Neumega ) subject type 1 Von Willebrand Disease ( VWD ) . The purpose establish clinical safety hemostatic efficacy rhIL-11 individual type 1 Von Willebrand disease . Study subject include follow subject : 1. age &gt; = 18 year age 2. diagnosis VWD confirm : 2a ) least 2 4 abnormal vWD-related coagulation test ; 2b ) past bleed history A total 10-16 subject anticipate enrol complete study . The specific aim study : 1. compare hemostatic efficacy three escalate dos rhIL-11 2. determine biologic effect rhIL-11 3. determine whether DDAVP , give seventh daily dose rhIL-11 , enhance hemostatic efficacy rhIL-11 4. compare safety three escalate dos rhIL-11 Efficacy base number percent increase VWD-related coagulation test normal range , least 2-3 time baseline . Safety base number frequency adverse reaction , include fever , headache , fatigue , arthralgia , myalgia , fluid retention , edema . The study last 4 week per subject , 24 month entire study .</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Males females 18 year age old Confirmed VWD 2 4 VWD coagulation test abnormal A past bleeding history No hormone , oral contraceptive , estrogen use past 8 week Willingness blood drawn Willingness sign inform consent Presence bleeding disorder , e.g . acquire VWD , thrombocytopenia Use estrogens , hormone , oral contraceptive past 8 week Use immunomodulatory experimental drug diuretic Pregnant lactate woman Past cardiac disease , congestive failure , arrhythmia ( e.g . atrial fibrillation , atrial flutter ) , hypertension , MI , stroke , thrombosis Past allergic reaction Neumega DDAVP Surgery within past 8 week Inability comply study protocol requirement Concomitant use antiplatelet drug , anticoagulant , dextran , aspirin , NSAIDs Treatment DDAVP , cryoprecipitate , whole blood , plasma , plasma derivative contain FVIII , VWF within 5 day study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Von Willebrand Disease</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Coagulation</keyword>
	<keyword>Hemostatic agent</keyword>
</DOC>